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Is There a Difference in Device-and Medication-Related Payments Made to Vascular Surgeons and Interventional Radiologists? Insights from the Open Payments Database
Brandon Brockbank, Michael F. Amendola. Virginia Commonwealth University, Richmond, Va
Objectives: The Open Payments program requires reporting of payments to licensed physicians. We sought to describe payments linked to medications or devices to vascular surgeons (VS) and interventional radiologist (IR).
Methods: We performed a descriptive analysis of the most recent Open Payments database released to the public by the Centers for Medicare & Medicaid Services for 2014 and 2015 calendar years. The total payments, drug product payments, and device payments made to VS and IR were obtained. We excluded all entries described as royalties, stock payments, grants, current or prospective ownership, and honorarium.
Results: Total payments in 2014 were $21,666,632 to IR and $12,872,852 to VS. Total payments in 2015 were $5,683,896 to IR and $12,674,746 to VS. Payment events related to medications and devices are reported in the Table. In examining the top 10 most common products found in each year and for each provider group, Xarelto (Janssen Pharmaceuticals) was the most frequently reported drug. There was no common device reported.
Conclusions: In studying the Open Payments Database, a marked reduction in total payments made to IR providers was found in 2015 from the previous year. Average medication-and device-related payments to each group for medications and devices were not statistically different. IR physicians received statistically more medication related payments than VS physicians. A common novel oral anticoagulant was a top 10 common medication related payment each year examined to each provider type.
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